The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.125
Bid: 17.75
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.75 (4.225%)
Open: 18.125
High: 18.125
Low: 18.125
Prev. Close: 18.125
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further sales expansion in Asia

6 Jul 2021 07:00

RNS Number : 2351E
OptiBiotix Health PLC
06 July 2021
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Further sales expansion in Asia

New Exclusive Distribution deal for CholBiome® in South Korea

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered a exclusive disbution deal with INSCOBEE INC ("Inscobee") for CholBiome® in the Republic of Korea.

 

Inscobee was established in 1970 and is listed on Korea's major stock market KOSPI since 1985. Its business activities consist of four fast growing business fields: the Smart grid, Mobile Virtual Network Operation, Cosmetics, and Bio-Tech, which includes its pharmaceutical, neutraceuticals, and supplement products with distribution in domestic and overseas markets. Inscobee's group turover was 57.8 billion Korean Won (USD 52.2m) last year and they are curently focused on expanding the health supplement area of their business.

 

Inscobee sell and promote nutraceuticals through hospitals and a consumer distribution base through Korean off-line channels such as Holland & Barrett stores, hypermarkets, home-shopping, and e-commerce channels including on-line malls, open markets, influencer markets and live commerce markets.

 

This agreement with Inscobee is another milestone in a series of deals which ProBiotix have entered into within Asia which help build LP LDL® and CholBiome's reputation and brand awareness in the region and open up the potentail for cross boarder e-commerce trading in China. ProBiotix Health has substantial momentum in the region, according to a recent article published in Nutraingredient Asia: Probiotics and CVD: OptiBiotix extends CholBiome range to APAC as blood pressure and cholesterol concerns rise (nutraingredients-asia.com).

 

Mr. Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health commened: "Incobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets where consumers seek innovative and effective natural solutions which stand out in the market. We welcome Inscobee into a global team of CholBiome® distributors serving medical doctors and cardiovascular specialists and directly to consumers via homeshopping, pharmacies and medical clinics. By entering deals on CholBiome® and LP LDL® in India, China, Malaysia, Singapore, Indonesia, Phillipines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets."

 

Mr. Seung-Hyeon Nam, Director of Inscobee Plc, commented: "At Inscobee, we are very pleased to introduce CholBiome® products to the Korean healthcare market. We believe CholBiome® has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation and expect that it will play a big role as a flaghship product of Inscobee's healthcare business. We look forward to a long and successful partnership with ProBiotix Health."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

 

 

 

 

   

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUMWMUPGGQA
Date   Source Headline
1st Sep 20172:41 pmRNSExercise of Options and Issue of Equity
30th Aug 20177:00 amRNSHalf-year Report
24th Aug 20177:00 amRNSUS product launch of LPLDL® at trade show
22nd Aug 20177:00 amRNSGlobal manufacturing & supply agreement with Sacco
31st Jul 20174:27 pmRNSTotal Voting Rights
26th Jul 20177:00 amRNSMarket launch for LPLDL® capsules in Germany
17th Jul 20177:00 amRNSSupply agreement with Pharmabiota Ltd
11th Jul 20177:00 amRNSSweetBiotix® development: Results of taste study
6th Jul 20177:00 amRNSGrant of Options
15th Jun 201712:30 pmRNSResult of AGM
15th Jun 20177:00 amRNSSupply agreement with HLH Biopharma GmbH
31st May 20177:00 amRNSHolding(s) in Company
16th May 20177:00 amRNSSuccessful launch of LPLDL and SlimBiome products
9th May 20177:00 amRNSLPLDL® Non-Exclusive European License Agreement
3rd May 20177:00 amRNSPresentation of abstract at conference
25th Apr 20178:50 amRNSFirst German sales
25th Apr 20177:00 amRNSFinal Results
4th Apr 20177:00 amRNSNotice of Results
29th Mar 201710:47 amRNSUK Investor Show attendance
24th Mar 20175:35 pmRNSHolding(s) in Company
21st Mar 201712:00 pmRNSIntention to float SkinBiotherapeutics
15th Mar 20177:00 amRNSConfirmation of Director appointments to the Board
8th Mar 20177:00 amRNSEuropean agreement with Sacco Srl
1st Mar 20177:00 amRNSLaunch of products at Vitafoods 2017
8th Feb 20179:30 amRNSExercise of Warrants and Issue of Equity
26th Jan 20172:06 pmRNSResult of General Meeting
24th Jan 20177:00 amRNSPresentation of research data
18th Jan 20177:00 amRNSAppointment of Sales and Marketing Director
17th Jan 20174:50 pmRNSHolding(s) in Company
13th Jan 20173:44 pmRNSExercise of Option and Issue of Equity
12th Jan 20177:00 amRNSPresentation of research data at ProBiota 2017
11th Jan 201710:04 amRNSExercise of Warrants and Issue of Equity
5th Jan 20177:00 amRNSAppointment of Commercial Director
3rd Jan 20177:00 amRNSIncreased investment in THWLC
23rd Dec 20167:00 amRNSNotice of General Meeting of Warrant Holders
13th Dec 20167:00 amRNSJoint Product Agreement with multinational
1st Dec 20167:00 amRNSExercise of Warrants and Issue of Equity
29th Nov 20167:00 amRNSScientific and Commercial Update
3rd Nov 20167:00 amRNSPresentation of data at European Microbiome Summit
26th Oct 20167:00 amRNSScientific and commerical update
20th Oct 20167:00 amRNSIncreased investment in SkinBiotix Ltd
5th Oct 20167:00 amRNSAppointment of a Chairman for SkinBiotix
28th Sep 20167:00 amRNSChange of Adviser
23rd Sep 20168:29 amRNSExercise of Warrants and Issue of Equity
14th Sep 20164:38 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSConsumer survey results of GoFigure products
25th Aug 20167:00 amRNSHalf-year Report
12th Aug 20163:11 pmRNSExercise of Warrants and Issue of Equity
9th Aug 20167:00 amRNSFirst products in Whole Foods Market Inc
3rd Aug 20167:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.